Gene:
FIP1L1
factor interacting with PAPOLA and CPSF1

PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.


Annotated Labels

  1. EMA Label for imatinib and ABL1,BCR,FIP1L1,KIT,PDGFRB
  2. HCSC Label for imatinib and ABI1,BCR,FIP1L1,KIT,PDGFRA,PDGFRB

last updated 10/25/2013

1. EMA Label for imatinib and ABL1,BCR,FIP1L1,KIT,PDGFRB

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) for imatinib (Glivec) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including KIT (CD117), BCR-ABL (Philadelphia chromosome), PDGFR and FIP1L1-PDGFRalpha rearrangements.

Annotation

Excerpt from the imatinib (Glivec) EPAR:

Glivec is indicated for the treatment of

  • adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.
  • adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.
  • adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.
  • adult patients with relapsed or refractory Ph+ ALL as monotherapy.
  • adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
  • adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR rearrangement.

Glivec is indicated for

  • the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).
  • the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.

This information is highlighted in the following sections:

Therapeutic indications, posology and method of administration, pharmacodynamic properties, package leaflet: information for the user.

The label also states that caution be taken when imatinib is taken concomittantly with CYP3A4 inhibitors and CYP3A4 inducers should be avoided.

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the imatinib EMA drug label.

*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.


2. HCSC Label for imatinib and ABI1,BCR,FIP1L1,KIT,PDGFRA,PDGFRB

Genetic testing required

Summary

The product monograph for imatinib (GLEEVEC) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including Kit (CD117), BCR-ABL1 (Philadelphia chromosome), PDGFR and FIP1L1-PDGFRalpha rearrangements.

Annotation

Excerpts from the imatinib (GLEEVEC) product monograph:

GLEEVEC(R), indicated for

  • the adjuvant treatment of adult patients who are at intermediate to high risk of relapse following complete resection of Kit (CD117) positive GIST.

GLEEVEC(R) has been issued non-conditional approval for the indications of

  • adult [or pediatric] patients with newly diagnosed, Philadelphia-chromosome-positive, chronic myeloid leukemia (CML) in chronic phase.
  • adult patients with Philadelphia chromosome-positive CML in blast crisis, accelerated phase or chronic phase (after failure of interferon-alpha therapy).
  • for use as a single agent for induction phase therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
  • adult patients with relapsed or refractory Ph+ ALL as monotherapy.
  • adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
  • adult patients with aggressive sub-types of systemic mastocytosis (ASM and SM-AHNMD) without the D816V c-Kit mutation. If c-Kit mutational status in patients with ASM or SM-AHNMD is not known or unavailable, treatment with GLEEVEC(R) may be considered if there is no satisfactory response to other therapies.
  • adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRalpha rearrangement.
  • adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).

For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the imatinib product monograph.

*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Alternate Names:  FIP1 like 1 (S. cerevisiae)
Alternate Symbols:  DKFZp586K0717; FIP1
PharmGKB Accession Id: PA134875694

Details

Cytogenetic Location: chr4 : q12 - q12
GP mRNA Boundary: chr4 : 54243803 - 54326103
GP Gene Boundary: chr4 : 54233803 - 54329103
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.
No related genes are available

Curated Information ?

Evidence Drug
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
imatinib
No related diseases are available

Publications related to FIP1L1: 2

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A case of myeloid neoplasm with FIP1L1-PDGFRA rearrangement without marked peripheral blood eosinophilia. Pharmacogenomics. 2016. Wang Jing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
EMA Initiatives and Perspectives on Pharmacogenomics. British journal of clinical pharmacology. 2014. Ehmann Falk, et al. PubMed

LinkOuts

Comparative Toxicogenomics Database:
81608
ModBase:
Q6UN15
HumanCyc Gene:
HS07234
HGNC:
19124

Common Searches